What You Should Know:
– Accenture has made a strategic investment in Ryght AI through its venture capital arm, aiming to modernize the sluggish clinical trial process. Ryght AI utilizes “agentic AI” and its proprietary AI Site Twin platform to create dynamic digital replicas of research sites, allowing pharmaceutical companies to optimize site selection and patient enrollment.
– The strategic collaboration seeks to remove the manual bottlenecks that delay life-saving therapies, combining Accenture’s global reach with Ryght’s specialized data models to accelerate drug development.
The End of the Manual Trial: Accenture Bets on Agentic AI to Fix Drug Development’s Biggest Bottleneck
For decades, the pharmaceutical industry has been plagued by a paradox: while the science of drug discovery moves at breakneck speed, the logistics of testing those drugs remain stuck in the analog age. Clinical trials are the most expensive and time-consuming phase of R&D, often stalled by the antiquated, manual process of selecting research sites and finding patients.
Today, Accenture signaled a major shift in how the industry approaches these hurdles. The global professional services giant announced a strategic investment in Ryght AI, a platform provider leveraging “agentic AI” and digital twin technology to overhaul clinical research design.
This investment, executed through Accenture Ventures, is not merely a financial transaction; it is a validation of the industry’s pivot toward autonomous, intelligent systems to manage the messy reality of human trials.
Solving the “Site Selection” Crisis
The core problem Ryght AI addresses is one of visibility and prediction. In the current landscape, identifying the right hospital or clinic to run a trial is a manual, heuristic-heavy process. Mistakes here are costly; selecting a site that fails to recruit patients can delay a study by months and burn millions in capital.
Ryght AI’s solution is the AI Site Twin platform. This technology creates dynamic digital replicas of clinical research sites globally. By ingesting real-time data on historical performance, patient demographics, and operational capacity, the platform allows sponsors to simulate feasibility before a single contract is signed.
“Generative and agentic AI are transforming the foundation of clinical research,” said Petra Jantzer, PhD, global lead of Life Sciences at Accenture. “With our investment in Ryght AI, we’re giving our life sciences clients the ability to fully leverage operational and scientific data and bring life-changing therapies to market faster.”
